Changes in the Predicted Adult Height after Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Idiopathic True Precocious Puberty.
10.6065/apem.2012.17.3.160
- Author:
Eun Byul KWON
1
;
Seung Joon LEE
;
Minah CHA
;
Se Young KIM
Author Information
1. Department of Pediatrics, Bundang Jesaeng General Hospital, Daejin Medical Center, Seongnam, Korea. odajulia@dmc.or.kr
- Publication Type:Original Article
- Keywords:
Puberty, precocious;
Gonadotropin-releasing hormone;
height
- MeSH:
Adult;
Gonadotropin-Releasing Hormone;
Humans;
Puberty, Precocious;
Retrospective Studies
- From:Annals of Pediatric Endocrinology & Metabolism
2012;17(3):160-168
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We evaluated the effects of the timing of treatment initiation with gonadotropin-releasing hormone agonist (GnRHa) on the change in predicted adult height (PAH) in girls with idiopathic true precocious puberty (TPP). METHODS: Data for this retrospective study were collected on 104 girls with TPP who were treated with GnRHa for 36 months, between January 2002 and March 2012. RESULTS: The PAH SDS differed before and after treatment in all patients (-1.91 +/- 1.47 vs. -1.37 +/- 1.17 after 1 year of treatment, -1.96 +/- 1.58 vs. -0.48 +/- 1.11 after 3 years of treatment) as well as in Group 1 (-2.15 +/- 1.54 vs. -1.51 +/- 1.20 after 1 year of treatment, -2.09 +/- 1.59 vs. -0.55 +/- 1.19 after 3 years of treatment) and Group 2 (-1.57 +/- 1.34 vs. -1.17 +/- 1.12 after 1 year of treatment, -1.50 +/- 1.55 vs. -0.21 +/- 0.74 after 3 years of treatment). This result could be due to improvement in bone age advancement during the treatment. The difference between mid-parental height SDS and PAH SDS was decreased after GnRHa treatment. However, the means of PAH SDS did not surpass the mid-parental height SDS. CONCLUSION: GnRHa treatment can preserve growth potential by slowing bone age progression, resulting in short adult height, but it cannot alter the genetic growth potential.
